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Abstract
Background: Next-generation DNA sequencing is opening new avenues for genetic association studies in
common diseases that, like deep vein thrombosis (DVT), have a strong genetic predisposition still largely
unexplained by currently identified risk variants. In order to develop sequencing and analytical pipelines for the
application of next-generation sequencing to complex diseases, we conducted a pilot study sequencing the
coding area of 186 hemostatic/proinflammatory genes in 10 Italian cases of idiopathic DVT and 12 healthy controls.
Results: A molecular-barcoding strategy was used to multiplex DNA target capture and sequencing, while
retaining individual sequence information. Genomic libraries with barcode sequence-tags were pooled (in pools of
8 or 16 samples) and enriched for target DNA sequences. Sequencing was performed on ABI SOLiD-4 platforms.
We produced > 12 gigabases of raw sequence data to sequence at high coverage (average: 42X) the 700-kilobase
target area in 22 individuals. A total of 1876 high-quality genetic variants were identified (1778 single nucleotide
substitutions and 98 insertions/deletions). Annotation on databases of genetic variation and human disease
mutations revealed several novel, potentially deleterious mutations. We tested 576 common variants in a case-
control association analysis, carrying the top-5 associations over to replication in up to 719 DVT cases and 719
controls. We also conducted an analysis of the burden of nonsynonymous variants in coagulation factor and
anticoagulant genes. We found an excess of rare missense mutations in anticoagulant genes in DVT cases
compared to controls and an association for a missense polymorphism of FGA (rs6050; p = 1.9 × 10-5, OR 1.45; 95%
CI, 1.22-1.72; after replication in > 1400 individuals).
Conclusions: We implemented a barcode-based strategy to efficiently multiplex sequencing of hundreds of
candidate genes in several individuals. In the relatively small dataset of our pilot study we were able to identify
bona fide associations with DVT. Our study illustrates the potential of next-generation sequencing for the discovery
of genetic variation predisposing to complex diseases.
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Background
Deep vein thrombosis (DVT) of the lower extremities, a
common thrombotic disease often complicated by acute
pulmonary embolism [1], has a strong genetic compo-
nent as established by family [2-4] and twin studies [5],
with a 3-fold increase in disease risk for siblings of indivi-
duals with DVT [2] and an estimated hereditary compo-
nent of 60% [3]. Genetic risk factors include rare
mutations in PROC, PROS1 and SERPINC1 leading to
the deficiencies of natural anticoagulant proteins (protein
C, protein S and antithrombin, respectively) and single
nucleotide polymorphisms (SNPs) of F5 (rs6025 or factor
V Leiden [FVL]) and of F2 (rs1799963 or prothrombin
G20210A) [6]. More recently, genome-wide association
studies (GWAS) identified associations of common SNPs
at 6 different genomic loci (CYP4V2, SERPINC1, GP6,
F5, ABO and HIVEP1) [7-9]. In spite of these recent
observations, however, genetic variants established to
influence the risk for DVT explain only a fraction of dis-
ease heritability [10].
Next-generation DNA sequencing is opening new ave-
nues for genetic association studies in complex diseases,
enabling to sequence large fractions of the human genome
(or even the entire genome) at unprecedented speed and
per-base costs. Re-sequencing the exome (i.e. the protein
coding area of the genome) or the entire genome is
becoming the gold standard for the identification of dis-
ease-causing mutations in Mendelian diseases [11-13].
However, the application of these techniques to common
diseases is still limited by the high costs and considerable
computational burden associated with the analysis of
numerous samples. Sequencing of a few hundred genes or
genomic loci is a much less expensive alternative to
whole-genome (or exome) sequencing, suitable for the
analysis of areas of the genome that are deemed to have
particular relevance in the pathophysiology of a given dis-
ease. However, this regional sequencing approach, which
requires sample multiplexing in order to achieve efficiency,
is technically challenging. Multiplexing on next-generation
sequencing platforms entails the use of DNA pools, which
is affected by limitations in downstream genetic associa-
tion analysis. These limitations include (a) loss of sensitiv-
ity to detect rare genetic variants, (b) uncertainty in allele
frequency estimations determined by the unequal repre-
sentation of samples within the pool, and (c) loss of indivi-
dual sequence data hampering direct genotype-phenotype
associations.
In this pilot study, we used genomic libraries with bar-
code sequence-tags as a means to overcome the limita-
tions of pooling. Using this approach we were able to
multiplex DNA-target capture and SOLiD sequencing
while retaining individual sequence information. In what
is one of the first practical applications of this technique,
we sequenced the coding area of 186 genes involved in
blood hemostasis/inflammation (i.e. two pivotal patho-
physiological mechanisms of DVT) in 10 Italian patients
with early-onset idiopathic DVT and 12 thrombosis-free
controls. The goal of this pilot study was to develop pipe-
lines for the application of next-generation sequencing in
the setting of DVT and to test different analytical
approaches for the identification of disease-associated
variants.
Methods
Patients
Cases of DVT were selected from 2139 unrelated patients
referred to the Angelo Bianchi Bonomi Hemophilia and
Thrombosis Center, Milan, (Italy) for diagnostic workout
and thrombophilia testing after a first episode of DVT of
the lower limbs in the years 1995-2010. Patients were
asked to bring to the center the diagnostic documenta-
tion of their thrombotic episodes and underwent a clini-
cal interview. DVT had been diagnosed by compression
ultrasonography or venography. All patients underwent a
complete thrombophilia screening, including measure-
ment of natural anticoagulant proteins, genotyping of
FVL and prothrombin G20210A and search for antipho-
spholipid autoantibodies. Coagulation factor VIII and
fibrinogen coagulant activities were also measured.
A patient selection flow-chart is shown in Additional
file 1 Figure S1. Patients selected for next-generation
sequencing were required to have (a) history of idiopathic
DVT of the lower limbs, (b) age of disease onset < 55
years, (c) wild-type FVL and prothrombin G20210A gen-
otypes, (d) absence of natural anticoagulant deficiencies,
(e) negative search for anti-phospholipid autoantibodies,
(f) been born in Lombardy, the 10 million people region
of Italy that has Milan as a regional capital. Since 42
patients matched these criteria, patients were further
prioritized based on age of onset, familial history of
venous or arterial thrombosis, completeness of clinical
information, DNA amount and quality. Patients included
in the replication were all the remaining 719 patients
with a first episode of idiopathic lower-limb DVT and
available DNA. Controls included in the study were
selected from a total of 1938 healthy Italian individuals
recruited among friends and non-consanguineous rela-
tives who accompanied patients to the Hemophilia and
Thrombosis Center and agreed to be tested for thrombo-
philia. Previous arterial or venous thrombosis in the con-
trols was excluded using a validated questionnaire [14].
Controls had similar age of the idiopathic DVT cases (±
5 years) and the same gender. Controls who underwent
next-generation sequencing were matched with the
patients for geographic provenience (born in Lombardy),
in order to minimize population stratification. In case
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more than one control matched the same patient, control
inclusion was random. The study was approved by the
Institutional Review Board of the Fondazione IRCCS Ca’
Granda - Ospedale Maggiore Policlinico and all subjects
gave their informed consent. Patient recruitment, sam-
pling and thrombophilia screening were carried out at
the Angelo Bianchi Bonomi Hemophilia and Thrombosis
Center, Milan (Italy). Next-generation DNA analysis and
replication PCR and Sanger sequencing and associated
analyses were carried out at the Human Genome Sequen-
cing Center (HGSC), Baylor College of Medicine, Hous-
ton (USA).
Target area selection
The protein coding exons, 3’ and 5’ UTRs, and the
intron-exon boundaries of 186 genes were chosen as
target area. Target genes included all coagulation factor
genes, anticoagulant genes and genes involved in fibri-
nolysis, platelet adhesion and aggregation, cell-cell inter-
action, endothelial activation and inflammation. The
genomic coordinate intervals corresponding to the target
area were obtained from the UCSC Genome Browser
database and sent to NimbleGen for probe design.
Probes were designed for all of the submitted intervals,
with slightly different genomic coordinates (i.e. tiled
regions). The final target area spanned 644, 472 bp.
Probes were arrayed on Roche NimbleGen HD2 2.1 M-
probe custom chips. The complete lists of target and
tiled coordinate-intervals and of the target genes are in
the Additional file 2 and Additional file 1 Table S1.
Experimental design
Two experiments were carried out. In the first experiment,
genomic libraries from 4 DVT patients (DVT_P_01,
DVT_P_02, DVT_P_03, DVT_P_04) and 4 controls
(DVT_C_01, DVT_C_02, DVT_C_03, DVT_C_04) were
captured on the same Roche NimbleGen HD2 chip and
sequenced in the same ABI SOLiD 4 spot (one quarter of
a slide). In the second, libraries from 8 cases (DVT_P_01,
DVT_P_05, DVT_P_06, DVT_P_07, DVT_P_08,
DVT_P_09, DVT_P_10, DVT_P_11) and 8 controls
(DVT_C_05, DVT_C_06, DVT_C_07, DVT_C_08,
DVT_C_09, DVT_C_10, DVT_C_11, DVT_C_12) were
captured on one Roche NimbleGen HD2 chip and
sequenced in two ABI SOLiD 4 spots. Sample DVT_P_11
failed capture during the second experiment. Patient
DVT_P_01 was sequenced twice as a quality control
procedure.
Genomic library preparation, barcoding and enrichment
of target DNA sequences
Two micrograms of genomic DNA were used to prepare
libraries of DNA fragments that were ligated with ABI
SOLiD P1-and P2-adaptors [15]. Different modified P2-
adaptors, each containing a specific DNA-tag sequence
(molecular barcode), were used for each individual
library. Libraries with barcodes were used to prepare
equimolar DNA pools of 8 and 16 samples. Four micro-
grams of DNA from each pool were hybridized on one
Roche NimbleGen HD2 chip.
ABI SOLiD 4 sequencing
Capture products underwent emulsion PCR with P1-
adaptor mediated attachment of clonally-amplified tem-
plates to loading beads. Beads were covalently attached
on glass slides at the P2-adaptor extremity. Sequencing
by oligonucleotide ligation and detection (SOLiD) was
performed on ABI SOLiD 4 platforms [15].
Read barcode assignment and mapping to the reference
genome
Reads with the barcodes were assigned to the corre-
sponding sample using custom Perl scripts and mapped
to reference human genome, NCBI36/hg18, using
BFAST software [16]. Reads that mapped on the same
starting and end coordinates, considered likely to be
PCR duplicates, were marked in the binary alignment/
mapping (BAM) files, where mapping information was
stored.
Genetic variant calls and quality control (QC)
Sorted BAM files were processed in a variant-calling pipe-
line consisting of a BAM filtering process and a variant
calling process. In the first step, duplicate reads were
eliminated from the BAM files, retaining only the read
with the top mapping quality at each pair of start and end
mapping coordinates. Also, reads with mapping quality
score of less than 50 were expunged from the BAM files.
In the variant-calling step, Samtools [17] was used to gen-
erate PILEUP files with read information at sites where
mismatches from the reference sequence were detected.
Consensus in the presence of mismatches, read- and base-
quality parameters were used as criteria to distinguish
genetic variants from sequencing errors, filtering high-
quality calls. In a final QC process, this set of calls was
further cleared from variants with an allele balance (var-
iant allele reads/total number of reference plus variant
allele reads) below 20% and/or with significant strand bias
(i.e. sites at which the variant sequence did not appear on
both forward and reverse reads) in spite of high variant
quality.
Variant annotation
Genetic variants were annotated on RefSeq database,
dbSNP129 and 1000 Genomes pilot release (March
2010) [18] using Annovar software [19]. Missense var-
iants were also annotated on SIFT [20] and Polyphen 2
[21].
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Association analysis
Several pieces of software have been developed to analyze
genotyping result of commercially SNP-genotyping arrays
(e.g. those used for GWAS), in particular the successful
PLINK package [22]. On the other hand, few tools are
available for genetic association analysis of next-genera-
tion sequencing datasets. For this reason we developed
Nxtgen2plink.rb, a software capable of generating
PLINK-compatible input files with phenotypic informa-
tion on sequenced individuals and genotype calls at each
site that was found to be variable in at least one of the
sequenced individuals. The software uses read alignment
and coverage information (BAM files), genetic-variant
calls (PILEUP files) and quality control information on
variants with low quality (also in the PILEUP file format)
to generate genotype calls across all individuals. Details
of the workflow of the Nxtgen2plink.rb software are pre-
sented in Additional file 1 Figure S2. Association analysis
was the carried out by PLINK and custom Perl and
Python scripts.
In our dataset we chose to carry out (a) association
analysis by Fisher’s exact test of all identified variants
that had at least a minor allele frequency (MAF) of 8%
in the entire dataset of cases plus controls (i.e. the
threshold MAF enabling a variant to reach a statistical
significance with p < 0.05 given the sample size) and a
genotype missingness of less than 10% and (b) ‘collap-
sing’ analysis comparing the total number of nonsynon-
ymous single nucleotide variants (SNVs) in coagulation
factor and anticoagulant protein genes in DVT cases
and controls.
Replication
We chose to carry over to replication in up to 719 idio-
pathic DVT patients and 719 matched controls the top-
5 variants from the single-variant association analysis.
Replication was carried out by PCR and Sanger sequen-
cing, which were chosen as replication techniques given
the high-throughput capacity of HGSC, their accuracy
and their potential to reveal neighboring genetic varia-
tion in linkage disequilibrium with or with similar effect
to that of the variant undergoing replication. Genotype
calls were performed automatically by SNP-detector [23]
and 10% of the calls were verified manually on chroma-
tograms. Replication comprised two stages (1) initial
replication in 284 individuals (2) full replication in 1438
individuals. We selected for stage 2 variants that given
their allele frequency and effect size estimated in stage 1
had 80% chances to be replicated at p < 0.005 in the
entire cohort of 1438 individuals. Genetic association
was carried out by PLINK. The interaction of rs6050
with FVL and prothrombin G20210A was tested using
PLINK with the epistasis option. Association of rs6050
with DVT after adjustment for covariates was assessed
by multivariable logistic regression using STATA 10
software.
Results
Patient selection and characteristics
After exclusion of patients who were non-Caucasian,
refused to give consent, had insufficient DNA amount or
low DNA quality (n = 374), 1765 patients with lower
limb DVT were included in the selection of idiopathic
cases for the study. Of these, 719 patients with idiopathic
DVT were further selected for the replication stage of
this study and another 11 patients were chosen for next-
generation sequencing after prioritizing the list of the 42
eligible patients selected on the basis of pre-specified cri-
teria (see ‘Patients’ in the Methods section). Of 1938
thrombosis-free Caucasian individuals recruited at the
Hemophilia and Thrombosis Center in the same period,
1703 who had available DNA were included in the selec-
tion of controls. Twelve controls underwent next-genera-
tion sequencing and 719 participated to the replication
stage of the study. The individual demographic, clinical
and laboratory features of the patients and controls who
underwent next-generation sequencing are in Additional
file 1 Table S2. Table 1 reports the characteristics of the
1438 individuals that participated to the replication stage.
Sequencing statistics
To sequence the 700-kilobase target area at an average
depth of coverage of 42X (after removal of duplicate
reads) in 22 samples, 12,040,000,000 bp and ~240 mil-
lion reads of raw sequence data were generated. Reads
were mapped on the human reference genome,
NCBI36/hg18, and non-duplicate reads were retained
and used for genotype calls. An average of 7% of the
reads mapped to the target region, corresponding to an
enrichment of more than 300-fold (the target area con-
stitutes 0.02% of the 3-gigabase human genome). On
average, 98, 4% of the target was covered at least once,
91% of the target area had at least the 10X coverage
required for confident variant calls and 80% had cover-
age > 20X indicating homogeneous high coverage of the
target area. Coverage statistics and representative histo-
grams can be found in the Additional file 1 (Table S3
and S4; Figure S3).
Type and frequency of identified genetic variants
In the 22 samples, 458 SNVs and 8 indels per individual
were identified in the target region. Additional file 1
Tables S5-S7 show the characteristics and annotation of
identified SNVs and indels. A total of 1778 high-quality
SNVs were identified. Of these, 487 were coding nonsy-
nonymous SNVs, which included 102 SNVs not present
in dbSNP129 and 1000 Genomes pilot release. A total
of 5 different nonsense variants were found (p.G2969X
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and p.G3170X in COL6A3; p.R412X in KNG1; p.R88X
in SERPINA10 and p.R615X in ZNF544). Ninety-eight
indels were called. The most frequent indel was an
intronic, single-nucleotide deletion in PLCG2 (chromo-
some 16, coordinate 80461934). Figure 1 shows the fre-
quency distribution of identified variants. Consistent
with previous observations [11,18], the frequency inter-
val between one observation and 5% yielded the highest
number of variants, the highest nonsynonymous/synon-
ymous ratio and the highest SIFT-predicted-damaging/
SIFT-predicted-benign ratio. To verify the validity of
variant calls and QC filters we (a) repeated the sequen-
cing of one of the samples (DVT_P_01) (b) sequenced
by PCR and Sanger all 22 samples at 35 sites where a
SNV was found (c) verified by Pyrosequencing 19
genotypes at sites with variants that did not pass QC.
Of 425 SNVs identified after QC in DVT_P_01 at the
second sequencing experiment, 405 (95.3%) had been
identified also in the first sequencing run of the same
sample, showing the high reproducibility of next-genera-
tion sequencing. Of 765 genotypes available from both
SOLiD and Sanger sequencing, 99.8% (697/698) of
homozygous wild-type genotypes and 97% (65/67) of
either heterozygous or homozygous variant genotypes
were in agreement. None of the variants that did not
pass QC was validated by Pyrosequencing.
Disease-associated variants in the target genes
In order to search for the presence of disease-associated
genetic variants, all identified SNVs were annotated on
Table 1 Characteristics of the individuals included in the replication stages of the study.
PATIENTS WITH IDIOPATHIC DVT CONTROLS
n= 719 719
GEOGRAPHIC ORIGIN, n (%)
Lombardy 453 (63) 490 (67)
Northern Italy other than Lombardy 89 (13) 84 (12)
Central Italy 30 (4) 20 (3)
Southern Italy and islands 109 (15) 107 (15)
Not available 38 (5) 18 (3)
MALE GENDER, n (%) 325 (45) 325 (45)
AGE, mean years (standard deviation) 42.5 (15) 42.5 (14)
PULMONARY EMBOLISM, n (%) 148 (20) /
REFERRED FOR MORE THAN ONE EPISODE, n (%) 167 (23) /
BODY MASS INDEX, kg/m2 25.9 (4.7) 24 (4)
FACTOR V LEIDEN (rs6025) GENOTYPE, n (%)
GG 611 (85) 696 (97)
AG 102 (14) 23 (3)
AA 6 (1) 0
PROTHROMBIN G20210A (rs1799963) GENOTYPE, n (%)
GG 654 (91) 695 (97)
AG 63 (8) 24 (3)
AA 2 (1) 0
NATURAL ANTICOAGULANT DEFICIENCIES, n (%)
Antithrombin 22 (3) 2 (0.2)
Protein C 26 (3) 2 (0.2)
Protein S 30 (4) 10 (1)
LABORATORY MEASUREMENTS, mean (standard deviation)
Antithrombin,% 97 (12) 99 (15)
Protein C, % 102 (27) 105 (22)
Protein S, % 105 (30) 111 (31)
Prothrombin time, international normalized ratio 1 (0.16) 0.99 (0.15)
Activated partial thromboplastin time, ratio 1 (0.1) 1 (0.1)
Coagulation factor VIII coagulant activity, % 142 (39) 114 (30)
Fibrinogen coagulant activity, % 304 (72) 291 (63)
Lotta et al. BMC Medical Genomics 2012, 5:7
http://www.biomedcentral.com/1755-8794/5/7
Page 5 of 11
the human gene mutation database (HGMD®), a data-
base that includes published mutations responsible for
human diseases [24]. A total of 27 variants were present
in HGMD® and are listed in Additional file 1 Table S8.
Of these variants, 9 had been reported in association
with thrombotic diseases (either venous or arterial
thrombosis) and 7 in association with DVT or DVT-
associated intermediate phenotypes (i.e. obesity and von
Willebrand factor [VWF] levels). Among these variants
were a missense variant of CYP4V2 gene (rs13146272)
reported to protect from DVT [7] (allele count in DVT
cases vs controls of this study: 3 vs 6), a 5’UTR-variant
of FGA gene found to increase DVT risk (rs2070011)
[25] (allele count in DVT cases vs controls: 12 vs 7) and
a variant reported to decrease circulating VWF levels
(rs216321) [26] (i.e. expected to have a protective effect
since high VWF levels increase DVT risk [27]; allele
count in DVT cases vs controls: 0 vs 3).
Nonsynonymous variation in coagulation genes
Because enhanced coagulation is one of the main patho-
genic mechanisms in DVT, particular attention was paid
to genetic variation in coagulation factor and anticoagu-
lant genes. A total of 127 variants were identified in 18
genes (FGA, FGB, FGG, F2, F3, F5, F7, F8, F9, F10, F11,
F12, F13A, F13B, PROC, SERPINC1, PROS1, PROZ). Of
these, 41 were missense variants, including 12 novel.
Twelve different missense variants were identified in the
large F5 gene and novel missense variants were found in
FGA (3), F7 (2), F12 (2), F5 (1), SERPINC1, PROC (2) and
PROZ. All missense variants identified in anticoagulant
and coagulation factor genes and their functional annota-
tion are summarized in Additional file 1 Table S9. There
was no significant difference in the burden of missense
variants of coagulation factor genes in DVT cases vs con-
trols, both at single-gene level and at collapsing analysis
of all coagulation genes, even when considering in the
analysis only variants that were predicted to produce
deleterious substitutions by Polyphen 2 or SIFT (see
Additional file 1 Table S9 for detailed allele counts). By
contrast, DVT cases displayed a higher number of mis-
sense variants in anticoagulant genes compared to con-
trols (Table 2; total count of 9 in cases vs 2 in controls,
average 0.9 vs 0.18; binomial distribution probability, p =
0.01). Of 5 different missense variants identified in cases,
4 were novel (conversely, only 8/36 variants identified in
coagulation factor genes were novel), 3 were predicted to
be potentially damaging for protein function by either
Polyphen 2 or SIFT and only one (the known SNP
rs3024772) was detected also in the control group, sug-
gesting that these missense variants are rare mutations
with likely deleterious effect on the encoded proteins.
Association analysis of common variants
Nxtgen2plink.rb was used to generate PLINK input files
from the BAM and PILEUP files of the 22 individuals
that had successfully undergone sequencing. Average
SNV-genotyping success was > 90%. Across the 1778
variable sites identified in the target area, we tested 576
variants that had allele frequency of at least 8% and geno-
typing success > 90% in a case-control association analy-
sis. The top-5 variants were selected for replication
(listed in Table 3). Of the 5 variants taken to replication
stage 1 in 284 individuals, 2 were sequenced in 719 cases
of idiopathic DVT of the lower limbs and 719 controls.
The variants that passed stage 1 were a low-frequency
Figure 1 Allele frequency distribution of single nucleotide variants with different functional annotation.
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missense polymorphism of PLCG2 (rs11548656, p.
H244R) and a common polymorphism of FGA (rs6050,
p.T331A). While PLCG2 p.H244R had no association
after sequencing in > 1400 individuals, FGA p.T331A
showed a statistically significant association with DVT in
a crude association analysis (p = 1.9 × 10-5, OR 1.45; 95%
CI, 1.22-1.72) and after adjustment for age and gender
(p = 0.0081, OR 1.39; 95% CI, 1.10-1.74). PCR and Sanger
sequencing also identified 7 missense variants in addition
to those targeted at these two loci (6 at FGA and 1 at
PLCG2). There was no association between these variants
and DVT at both single-variant and collapsing case-con-
trol association analysis. Variant features are summarized
in Additional file 1 Table S10. The association of rs6050
with DVT was further tested in multivariable logistic
regression models adjusting for several covariates. The
association between rs6050 and DVT remained statisti-
cally significant after adjustment for age, gender and plas-
matic levels of fibrinogen (p = 0.0001, OR 1.39; 95% CI,
1.10-1.74); and for age, gender, fibrinogen levels, body
mass index, FVL and prothrombin G20210A (p < 0.0001,
OR 1.41; 95% CI, 1.10-1.81). We also tested the interac-
tion (i.e. deviation of the cumulative effect from an addi-
tive model) between rs6050 and FVL and between rs6050
and prothrombin G20210A. Both tests were negative
(p = 0.44 for interaction with FVL and p = 0.89 for inter-
action with prothrombin G20210A).
Discussion
This pilot study is one of the first applications of next-gen-
eration sequencing in DVT. Sequencing by oligonucleotide
ligation and detection was used to resequence the protein-
coding areas of 186 hemostatic/pro-inflammatory genes in
cases and controls of DVT. This regional sequencing
approach enabled the simultaneous analysis of several doz-
ens of genes in many samples at a fraction of the cost and
computation required for whole-exome and whole-gen-
ome analysis. At the current level of multiplexing (i.e. up
to 64 samples per SOLiD slide, 16 per spot), the analysis
of our target area in one sample costs one tenth of a high-
coverage exome-sequencing and one hundredth of a high-
coverage whole-genome sequencing, with similar propor-
tions in the saving of computational time (3 hours for read
mapping vs the few days of whole-exome or the more than
1 week of whole-genome datasets) and information sto-
rage-capacity requirements (300 MB per BAM file vs 40
GB per BAM for whole-exome or 400 GB for whole-gen-
ome sequencing). For these reasons, regional sequencing
is ideal to interrogate relatively small genomic areas
deemed of particular functional relevance in a disease.
Potential applications of this approach are the sequencing
of positional candidate genes or genomic loci identified by
genome-wide linkage or association analysis [28], the
large-scale replication of the initial findings of exome and
whole-genome resequencing studies and the rapid screen-
ing of disease-genes in those Mendelian diseases that have
several different causal genes [29].
In the field of DVT, the importance of being able to ana-
lyze all known hemostatic genes (i.e. the ‘hemostateome’)
has been recently highlighted by Fechtel et al. [30]. The
simultaneous sequencing of all hemostatic genes in
affected individuals is ideal to study specific combinations
of variants in the hemostatic pathway acting in synergy to
confer DVT-predisposition. This type of approach has the
potential to reveal new disease-predisposing mechanisms,
besides the identification of isolated variants that show sta-
tistical association with the disease. In this study, the use
of molecular barcoding allowed multiplexing without loss
of individual sequence information, which is required to
fully exploit the potential of sequence data. Sequencing of
the 186 genes in 22 individuals yielded more than 1700
genetic variants of different functional type and frequency.
Annotation of identified variants revealed several disease-
associated variants, a proportion of which had already
been reported in association with DVT. Many novel var-
iants with potentially deleterious effect on the function of
key hemostatic proteins were also found. These results are
consistent with the recent report by Dewey et al. of the
Table 2 Nonsynonymous single nucleotide variants in anticoagulant genes.
Gene Chromosome Coordinate Substitution Transcript
ID
Protein
change
dbSNP129 1000 Genomes
CEU
population,
allele
frequency
SIFTa Polyphen
2b
Alleles
cases
Alleles
controls
PROC chr2 127895370 C > T NM_000312 p.R38W Novel not present Dam Prd 2 0
127902716 C > A p.H370Q Novel not present Ben Ben 1 0
SERPINC1 chr1 172150549 G > A NM_000488 p.P58L Novel not present Dam Pod 1 0
PROZ chr13 112861006 C > G NM_003891 p.L11V Novel not present Ben Ben 3 0
112874101 G > A p.R295H rs3024772 not present Ben Prd 2 2
a SIFT-based annotation results, Dam indicates that the mutation is predicted to affect protein function (i.e. ‘damaging’), Ben indicates that the mutation is
predicted to be tolerated (i.e.’benign’).
b Polyphen 2-based annotation results. Prd indicates that the mutation is predicted to be ‘probably damaging’, Pod indicates that the mutation is predicted to
be ‘possibly damaging’, Ben indicates that the mutation is predicted to be ‘benign’.
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Table 3 Common variant association results.
Variant information Discovery Replication stage 1 and 2 (combined)
Location Substitution Gene Functional
annotation
Protein dbSNP129 Alleles
cases
Alleles
controls
p = Effective sample
size cases
MAF
cases, %
(n)
Effective sample
size controls
MAF
controls, %
(n)
p= OR 95%
CI
chr4:155727040 T > C FGA exon -
missense
p.
T331A
rs6050 10 4 0.004 709 32 (453) 702 22 (312) 1.9 ×
10-5
1.45 1.22-
1.72
chr16:80474413 A > G PLCG2 exon -
missense
p.
H244R
rs11548656 4 0 0.013 711 6 (88) 705 6 (83) 0.73 1.05 0.77-
1.43
chr4:122837138 T > C ANXA5 Intron Na rs2306416 4 0 0.013 139 15 (41) 138 15 (42) 0.97 0.96 0.60-
1.54
chr8:42164111 G > A PLAT exon -
synonymous
Na rs1058720 11 3 0.002 139 47 (131) 139 44 (124) 0.61 1.10 0.79-
1.54
chr11:47311481 T > C MYBPC3 Intron Na rs11570115 5 0 0.004 137 11 (30) 139 9 (26) 0.63 1.19 0.68-
2.07
MAF indicates minor allele frequency; OR, odds ratio; CI, confidence interval; Na, not applicable (the variant does not cause protein sequence changes).
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genome sequence of a family quartet in which the father
had a history of DVT and pulmonary embolism [31]. In
the study, the authors identified four different novel non-
synonymous variants in DVT-risk genes and other known
thrombophilia associated variants.
In our study, we adopted different analytical
approaches to reveal potential associations with the dis-
ease at both single-variant and gene/pathway levels.
Although the number of analyzed individuals was very
small, it was possible to find statistically significant and
biologically plausible associations with DVT. An
increased burden of rare missense mutations in anticoa-
gulant genes was found in DVT cases compared to con-
trols. Single-variant association analysis followed by
replication genotyping in > 1400 individuals identified
an association for the rs6050 SNP in FGA. The excess
of rare missense mutations in anticoagulant genes in
patients in whom the deficiencies of natural anticoagu-
lants had been excluded with biochemical assays sug-
gests that a fraction of idiopathic DVT cases might be
affected by ‘unrecognized’ anticoagulant deficiencies,
caused by mutations that impart functional effects to
which currently used biochemical assays are not sensi-
tive. The association of rs6050, already described by pre-
vious candidate SNP studies, was here identified by an
agnostic screening of several dozen genes. The associa-
tion of rs6050 was reported in 4 studies focusing on
venous thromboembolism (VTE), therefore including
cases of pulmonary embolism without a diagnosis of
DVT [25,32-34]. Two of these studies were very small,
with total sample size (cases and controls) of less than
500 individuals [25,32]. Ours is the second largest of all
the studies on rs6050 both in terms of DVT cases inves-
tigated and overall statistical power. Thus, along with
previous reports, this study makes of rs6050 one of the
most widely replicated variants in DVT. The mechan-
isms for the association of rs6050 with DVT/VTE are
not fully understood. FGA rs6050 was reported to result
in enhanced coagulation factor XIII-mediated cross-link-
ing of fibrin alpha-chain [35] and to be associated with
increased FGA transcription [32]. In this report we
found no association of FGA rs6050 with plasmatic
fibrinogen activity, but the fact that rs6050 is a missense
SNP and that the amino acid substitution is considered
as ‘possibly damaging’ by Polyphen 2 indeed suggest
that the risk for DVT is conferred by an alteration of
fibrinogen-alpha chain function.
Limitations
The approach proposed in this study has limitations.
The use of DNA target capture may introduce bias in
the detection of genetic variants by allele-selective cap-
ture. Both the use of target capture and the short-read
length of next-generation sequencing platforms
constrain comprehensive analysis of copy number varia-
tion (CNV), an important source of genetic variability.
However, these limitations can be minimized by increas-
ing sequence coverage and by using complementary
genetic analyses (e.g. array-based CNV-ascertainment).
Restricting the analysis to a few hundred candidate
genes may limit the chance to detect novel associations.
On the other hand, the efficiency and cost effectiveness
of regional sequencing are ideal for the thorough, large-
scale analysis of genetic variation in specific biological
pathways such as hemostasis. This approach may pro-
vide deep understanding of the mechanisms by which
multiple variants in the same biological pathway shape
individual predisposition to complex phenotypes.
Conclusions
Using a molecular-barcode based technique for sample
multiplexing on next-generation DNA sequencing plat-
forms we sequenced the coding areas of 186 hemo-
static/proinflammatory genes in cases and controls of
DVT. We were able to detect known disease-associated
variants as well as novel potentially-deleterious variants
in disease-associated genes. Our results illustrate the
potential of next-generation gene sequencing for the dis-
covery of genetic variation predisposing to common dis-
eases and for the study of inherited thrombophilia.
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